Liven Pharma Limited (PSX: LIVEN) reported a 75.56% year-on-year reduction in its net loss to Rs7.37 million for the quarter ended September 30, 2026, compared to a net loss of Rs30.16 million recorded in the same period last year.
The company's basic and diluted loss per share (LPS) improved to Rs0.07 from a restated Rs0.28 in the corresponding quarter of the previous year. The narrower loss was primarily driven by an 81.66% reduction in other expenses, lower administrative and selling expenses, a surge in other income to Rs7.60 million (from Rs4,032), and a higher taxation credit of Rs2.71 million.
However, operational profitability faced pressure as sales cost expanded by 244.93% to Rs16.87 million, pushing the company into a gross loss of Rs2.57 million despite a 62.04% increase in total revenue.
| Description | Q1 2026 (PKR) | Q1 2025 (PKR) | Change (%) |
|---|---|---|---|
| Sales | 14,293,355 | 8,820,810 | 62.04% |
| Cost of Sales | (16,865,196) | (4,889,428) | 244.93% |
| Gross Profit / (Loss) | (2,571,841) | 3,931,382 | N/A |
| Administrative Expenses | (7,060,596) | (9,555,737) | -26.11% |
| Selling & Distribution Expenses | (3,476,898) | (4,765,879) | -27.05% |
| Other Expenses | (3,799,999) | (20,720,838) | -81.66% |
| Other Income | 7,600,294 | 4,032 | N/A |
| Net Loss | (7,371,540) | (30,157,472) | -75.56% |
| LPS (PKR) | (0.07) | (0.28) | -75.00% |
Read the full story on the original publisher’s website.
Open original article